Loading...

FENC FENNEC PHARMACEUTICALS INC Product Launches 8-K Filing

FNNC

FNC

FENNEC PHARMACEUTICALS INC

(FENC)

2025 8-K

Stock Options Granted

Clinical Abstracts Acceptance

Clinical Study Announcement

Financial Results Announced

Legal Settlement Agreement

Study Announcement

PEDMARK Data Update

Clinical Study Launch

Positive Trial Results

Debt Redemption Completed

Share Issuance Details

Public Offering Announcement

Financial Results

Note Redemptions

Management Appointments

Departure and Appointment o...

Departure of Directors or C...

Annual Meeting of Shareholders

Earnings Reports

Entry into License and Supp...

Amendment to Form 8-K

FDA Reminder for PEDMARK

Financing Transaction

Financial Results Announcement

Departure of Directors or C...

Financial Results Announcement

Annual Meeting of Shareholders

FDA Grant Orphan Drug Exclu...

External Links:

On December 2, 2025, Fennec Pharmaceuticals announced positive results from a clinical trial for PEDMARK®, the first FDA-approved treatment to reduce cisplatin-induced ototoxicity in pediatric patients. This filing is significant for the company as it highlights advancements in their product offerings.

AI Assistant

FENNEC PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.